Division of Cardiology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Division of Cardiology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Am J Cardiol. 2021 May 15;147:52-57. doi: 10.1016/j.amjcard.2021.01.039. Epub 2021 Feb 20.
There is growing evidence that COVID-19 can cause cardiovascular complications. However, there are limited data on the characteristics and importance of atrial arrhythmia (AA) in patients hospitalized with COVID-19. Data from 1,029 patients diagnosed with of COVID-19 and admitted to Columbia University Medical Center between March 1, 2020 and April 15, 2020 were analyzed. The diagnosis of AA was confirmed by 12 lead electrocardiographic recordings, 24-hour telemetry recordings and implantable device interrogations. Patients' history, biomarkers and hospital course were reviewed. Outcomes that were assessed were intubation, discharge and mortality. Of 1,029 patients reviewed, 82 (8%) were diagnosed with AA in whom 46 (56%) were new-onset AA 16 (20%) recurrent paroxysmal and 20 (24%) were chronic persistent AA. Sixty-five percent of the patients diagnosed with AA (n=53) died. Patients diagnosed with AA had significantly higher mortality compared with those without AA (65% vs 21%; p < 0.001). Predictors of mortality were older age (Odds Ratio (OR)=1.12, [95% Confidence Interval (CI), 1.04 to 1.22]); male gender (OR=6.4 [95% CI, 1.3 to 32]); azithromycin use (OR=13.4 [95% CI, 2.14 to 84]); and higher D-dimer levels (OR=2.8 [95% CI, 1.1 to 7.3]). In conclusion, patients diagnosed with AA had 3.1 times significant increase in mortality rate versus patients without diagnosis of AA in COVID-19 patients. Older age, male gender, azithromycin use and higher baseline D-dimer levels were predictors of mortality.
越来越多的证据表明,COVID-19 会引起心血管并发症。然而,关于 COVID-19 住院患者房性心律失常(AA)的特征和重要性的数据有限。分析了 2020 年 3 月 1 日至 4 月 15 日期间在哥伦比亚大学医学中心诊断为 COVID-19 并住院的 1029 例患者的数据。通过 12 导联心电图记录、24 小时遥测记录和植入式设备询问来确认 AA 的诊断。回顾了患者的病史、生物标志物和住院过程。评估的结果是插管、出院和死亡率。在回顾的 1029 例患者中,82 例(8%)被诊断为 AA,其中 46 例(56%)为新发 AA,16 例(20%)为阵发性复发性 AA,20 例(24%)为慢性持续性 AA。诊断为 AA 的患者中有 65%(n=53)死亡。与没有 AA 的患者相比,诊断为 AA 的患者死亡率显著更高(65%比 21%;p<0.001)。死亡率的预测因素为年龄较大(优势比(OR)=1.12,[95%置信区间(CI),1.04 至 1.22]);男性(OR=6.4 [95% CI,1.3 至 32]);使用阿奇霉素(OR=13.4 [95% CI,2.14 至 84]);以及更高的 D-二聚体水平(OR=2.8 [95% CI,1.1 至 7.3])。总之,与没有诊断为 AA 的 COVID-19 患者相比,诊断为 AA 的患者的死亡率显著增加了 3.1 倍。年龄较大、男性、使用阿奇霉素和较高的基线 D-二聚体水平是死亡率的预测因素。